<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We tested the hypothesis that an anticardiolipin antibody (aCL) titer of &gt; or = 10 IgG <z:chebi fb="0" ids="16247">phospholipid</z:chebi> (GPL) at the time of an index <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> is associated with an increased risk of subsequent thrombo-occlusive events or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>First-time <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients from the <z:hpo ids='HP_0003613'>Antiphospholipid Antibodies</z:hpo> and <z:hpo ids='HP_0001297'>Stroke</z:hpo> Study Group's Prevalence Study were followed prospectively for a median time of 24 months for any thrombo-occlusive event or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>There was no significant difference for the endpoint of <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo>, pulmonary <z:mpath ids='MPATH_110'>embolus</z:mpath>, or arterial <z:mpath ids='MPATH_110'>embolus</z:mpath> between the aCL positive and negative patients </plain></SENT>
<SENT sid="3" pm="."><plain>Although a single aCL value of &gt; or = 10 GPL at the time of an initial <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> is a significant independent risk factor for <z:hpo ids='HP_0001297'>stroke</z:hpo>, when adjusted for other <z:hpo ids='HP_0001297'>stroke</z:hpo> risk factors in our study population, aCL positivity did not confer a significantly increased risk for subsequent thrombo-occlusive events or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
</text></document>